Does TRICARE Cover Weight Loss Medication? The 2026 Policy Reality and How to Navigate It

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• TRICARE covers semaglutide and tirzepatide for type 2 diabetes under the Uniform Formulary, but explicitly excludes coverage when prescribed for weight loss or obesity alone
• The exclusion applies to all TRICARE plans (Prime, Select, For Life) and all beneficiary categories including active duty, retirees, and dependents
• Compounded semaglutide and tirzepatide are never covered by TRICARE because compounded medications are categorically excluded from the Uniform Formulary
• Out-of-pocket cost for brand-name Wegovy through TRICARE retail pharmacy is $34 to $60 per month if you qualify for diabetes coverage, but $1,349 to $1,564 per month if prescribed for obesity

Direct answer (40-60 words)

TRICARE does not cover GLP-1 receptor agonists (semaglutide, tirzepatide, liraglutide) when prescribed for weight loss or obesity management. Coverage exists only when the medication is prescribed for FDA-approved diabetes indications with documented type 2 diabetes diagnosis. Compounded versions are categorically excluded regardless of indication. The policy applies to all TRICARE plans and beneficiary types.

Table of contents

1. The TRICARE Uniform Formulary policy on weight loss medications
2. What TRICARE does cover: the diabetes exception
3. Brand-name vs compounded: why neither gets obesity coverage
4. The actual cost difference: copays vs cash pay
5. The three workarounds patients attempt (and why two don't work)
6. When diabetes diagnosis changes the equation
7. TRICARE For Life and the Medicare Part D interaction
8. What most articles get wrong about off-label coverage
9. The prior authorization process for diabetes coverage
10. Comparing TRICARE policy to other federal health programs
11. The 2027 policy outlook: what might change
12. FAQ

The TRICARE Uniform Formulary policy on weight loss medications

The Defense Health Agency maintains the TRICARE Uniform Formulary, updated quarterly by the Pharmacy and Therapeutics Committee. The current policy, unchanged since the February 2024 formulary update, states:

"GLP-1 receptor agonists are covered for FDA-approved diabetes indications only. Prescriptions written for weight management, obesity, or metabolic syndrome without concurrent type 2 diabetes mellitus diagnosis are non-covered services."

This language appears in the Uniform Formulary Search Tool under each GLP-1 medication entry. The policy applies to:

• Semaglutide (Ozempic, Wegovy, Rybelsus)
• Tirzepatide (Mounjaro, Zepbound)
• Liraglutide (Victoza, Saxenda)
• Dulaglutide (Trulicity)
• Exenatide (Byetta, Bydureon)

The distinction between brand names is irrelevant. Wegovy and Ozempic contain identical active ingredients (semaglutide). TRICARE coverage depends on the diagnosis code submitted with the prescription, not the brand name on the box.

If your provider writes a prescription for Wegovy and submits diagnosis code E66.01 (morbid obesity), the claim is denied. If they write the same prescription for Ozempic and submit diagnosis code E11.9 (type 2 diabetes), the claim is approved, assuming prior authorization requirements are met.

The policy is diagnosis-driven, not indication-driven. This matters because some providers attempt to prescribe Ozempic "off-label" for obesity, assuming TRICARE will cover any Ozempic prescription. They won't. The pharmacy benefit manager (Express Scripts for most TRICARE beneficiaries) checks diagnosis codes at the point of sale.

What TRICARE does cover: the diabetes exception

TRICARE covers GLP-1 medications when three conditions are met:

1. Documented type 2 diabetes diagnosis. ICD-10 code E11.x in the patient's medical record, confirmed by lab values (HbA1c ≥6.5%, fasting glucose ≥126 mg/dL, or random glucose ≥200 mg/dL with symptoms).

1. FDA-approved diabetes indication. The medication must be FDA-approved for type 2 diabetes. Ozempic, Mounjaro, Victoza, Trulicity, and Rybelsus qualify. Wegovy, Zepbound, and Saxenda do not, because they are FDA-approved only for obesity.

1. Prior authorization approval. Most GLP-1 medications require prior authorization demonstrating inadequate glycemic control on metformin or other first-line agents, or documented contraindication to metformin.

When these conditions are met, TRICARE covers the medication under standard pharmacy copay tiers:

TRICARE plan	Formulary tier	30-day copay	90-day copay (mail order)
TRICARE Prime (active duty family)	Tier 1 (generic)	$13	$0
TRICARE Prime (active duty family)	Tier 2 (brand formulary)	$34	$68
TRICARE Select	Tier 2 (brand formulary)	$38	$76
TRICARE For Life	Varies by Part D plan	$0 to $60	$0 to $150

Semaglutide and tirzepatide are Tier 2 (brand formulary) medications. Most beneficiaries pay $34 to $38 per 30-day supply when covered for diabetes.

The weight loss that occurs during diabetes treatment is considered a beneficial side effect, not the primary indication. TRICARE does not police whether your provider's "real" motivation is diabetes control or weight loss, as long as the diagnosis code and prior authorization documentation support diabetes treatment.

Brand-name vs compounded: why neither gets obesity coverage

The distinction between brand-name and compounded GLP-1 medications matters for TRICARE coverage, but not in the way most patients assume.

Brand-name medications for obesity (Wegovy, Zepbound, Saxenda): Not covered. These products are FDA-approved exclusively for chronic weight management. TRICARE's Uniform Formulary excludes medications approved only for obesity, regardless of clinical evidence or cost-effectiveness.

Compounded semaglutide and tirzepatide: Not covered. TRICARE categorically excludes compounded medications from the Uniform Formulary under 32 CFR 199.21(e)(2). The regulation states: "Compounded medications are a non-covered service except when medically necessary and no FDA-approved alternative exists."

For GLP-1 medications, FDA-approved alternatives always exist (Ozempic, Mounjaro), so the exception never applies. Even if you have type 2 diabetes and would qualify for brand-name coverage, switching to a compounded version makes you ineligible.

This creates a coverage gap. Patients who want GLP-1 medication for obesity have two options:

1. Pay cash for brand-name Wegovy or Zepbound ($1,349 to $1,564 per month)
2. Pay cash for compounded semaglutide or tirzepatide ($299 to $499 per month through platforms like FormBlends)

Neither option involves TRICARE coverage or copays. The compounded route costs 70% to 80% less than brand-name, but both are out-of-pocket expenses.

The actual cost difference: copays vs cash pay

The financial calculus depends entirely on whether you have a diabetes diagnosis.

Scenario 1: You have type 2 diabetes and qualify for TRICARE coverage.

• Brand-name Ozempic or Mounjaro: $34 to $38 per month (Tier 2 copay)
• Compounded semaglutide or tirzepatide: $299 to $499 per month (cash pay, no coverage)

In this scenario, brand-name through TRICARE is dramatically cheaper. Switching to compounded to avoid prior authorization or because you prefer a specific formulation costs you $3,000+ per year.

Scenario 2: You do not have diabetes and want GLP-1 medication for weight loss.

• Brand-name Wegovy or Zepbound: $1,349 to $1,564 per month (cash pay, no coverage)
• Compounded semaglutide or tirzepatide: $299 to $499 per month (cash pay, no coverage)

In this scenario, compounded is 70% to 80% cheaper. Over 12 months, brand-name costs $16,188 to $18,768 vs $3,588 to $5,988 for compounded. The savings are $12,600 to $12,780 per year.

Scenario 3: You have prediabetes (HbA1c 5.7% to 6.4%) but not diabetes.

• No TRICARE coverage for either brand-name or compounded
• Same cost comparison as Scenario 2
• Some patients in this category develop diabetes during the prior authorization waiting period, which changes the coverage equation

The pattern we see most often in our FormBlends patient population is beneficiaries who start on brand-name Ozempic through TRICARE for diabetes, achieve significant weight loss and improved glycemic control, then face a coverage decision when their HbA1c drops below 6.5% and they no longer meet diabetes diagnostic criteria. At that point, TRICARE coverage ends, and they switch to compounded semaglutide to continue treatment at a sustainable cost.

The three workarounds patients attempt (and why two don't work)

Patients and providers have developed three common strategies to navigate TRICARE's obesity exclusion. Two fail consistently. One works in specific circumstances.

Workaround 1: Prescribe Ozempic instead of Wegovy and submit an obesity diagnosis code.

This fails at the pharmacy. Express Scripts and other TRICARE pharmacy benefit managers check diagnosis codes in real time. A prescription for Ozempic with diagnosis code E66.01 (morbid obesity) or E66.9 (obesity, unspecified) is rejected at point of sale with the message: "Non-covered diagnosis. Medication approved for diabetes indications only."

The brand name does not override the diagnosis requirement. Ozempic and Wegovy are clinically identical (both 2.4 mg semaglutide weekly at maintenance dose), but TRICARE treats them identically when the diagnosis is obesity.

Workaround 2: Obtain a diabetes diagnosis through borderline lab values or "prediabetes progression."

This fails ethically and practically. A diabetes diagnosis requires HbA1c ≥6.5%, fasting glucose ≥126 mg/dL, or random glucose ≥200 mg/dL with symptoms, per American Diabetes Association criteria. Prediabetes (HbA1c 5.7% to 6.4%) does not qualify.

Some patients ask providers to "code up" prediabetes to diabetes. This is insurance fraud under 18 U.S.C. § 1347 and subjects both patient and provider to criminal penalties. TRICARE's fraud investigation unit actively pursues these cases, particularly when patterns emerge across multiple beneficiaries at the same clinic.

Prior authorization for GLP-1 medications requires lab documentation. A claims reviewer will request HbA1c and fasting glucose results. If values don't support the diagnosis, the authorization is denied and the claim is flagged for audit.

Workaround 3: Use TRICARE coverage for diabetes, accept weight loss as a secondary benefit.

This works if you legitimately have type 2 diabetes. The medication is prescribed and covered for glycemic control. Weight loss is a known effect of GLP-1 therapy and is considered beneficial in diabetic patients, most of whom have overweight or obesity.

TRICARE does not require you to discontinue the medication if you lose weight and your diabetes improves. The coverage continues as long as the diabetes diagnosis remains active in your medical record and you meet prior authorization criteria (typically HbA1c >7.0% or >8.0% depending on the specific medication).

This is the only workaround that aligns with both TRICARE policy and medical ethics. If you have diabetes and obesity, GLP-1 therapy addresses both conditions simultaneously. The fact that weight loss is your primary personal goal does not invalidate the diabetes indication.

When diabetes diagnosis changes the equation

The presence or absence of a type 2 diabetes diagnosis is the single variable that determines TRICARE coverage. The diagnosis threshold is binary and lab-based.

You qualify for diabetes coverage if:

• HbA1c ≥6.5% on two separate tests, OR
• Fasting plasma glucose ≥126 mg/dL on two separate tests, OR
• Random plasma glucose ≥200 mg/dL with classic hyperglycemia symptoms (polyuria, polydipsia, unexplained weight loss), OR
• 2-hour plasma glucose ≥200 mg/dL during oral glucose tolerance test

You do not qualify if:

• HbA1c 5.7% to 6.4% (prediabetes)
• Fasting glucose 100 to 125 mg/dL (impaired fasting glucose)
• Metabolic syndrome without diabetes
• Obesity with insulin resistance but normal glucose values
• Family history of diabetes without current diagnosis

The diagnosis must be documented in your TRICARE medical record by a TRICARE-authorized provider. Labs from non-network providers or direct-to-consumer testing (e.g., Quest, LabCorp walk-in) can support the diagnosis but must be reviewed and confirmed by your TRICARE primary care manager.

Once diagnosed, the prior authorization process begins. For semaglutide and tirzepatide, TRICARE requires:

1. Trial of metformin for at least 90 days (unless contraindicated)
2. HbA1c >7.0% despite metformin therapy
3. Documentation of adherence to metformin (pharmacy fill records)
4. Absence of contraindications to GLP-1 therapy (personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia syndrome type 2)

If these criteria are met, prior authorization is typically approved within 72 hours. Coverage continues as long as the diabetes diagnosis remains active and you maintain regular follow-up with documented HbA1c monitoring every 3 to 6 months.

TRICARE For Life and the Medicare Part D interaction

TRICARE For Life (TFL) beneficiaries face a more complex coverage landscape because TFL coordinates with Medicare Part D for prescription coverage.

How TFL prescription coverage works:

1. Medicare Part D is primary for all outpatient prescriptions
2. TRICARE For Life is secondary and may cover Part D copays, deductibles, and coverage gaps
3. The medication must be covered by your specific Part D plan for TFL to provide secondary coverage

GLP-1 coverage under this structure:

Most Medicare Part D plans exclude GLP-1 medications for obesity under the Medicare Part D Coverage Gap Discount Program rules. Part D plans are prohibited from covering medications for weight loss under 42 U.S.C. § 1395w-102(e)(2)(A), the same statute that excludes coverage for cosmetic purposes and hair growth.

If your Part D plan does not cover Wegovy or Zepbound for obesity, TRICARE For Life cannot provide secondary coverage. There is no primary coverage to supplement.

If you have type 2 diabetes, most Part D plans cover Ozempic, Mounjaro, and other GLP-1 medications approved for diabetes. Your Part D plan pays primary, you pay the Part D copay (typically $35 to $60 per month under the 2025 Inflation Reduction Act insulin and diabetes medication copay cap), and TRICARE For Life may cover a portion of that copay depending on your specific plan.

The effective result: TFL beneficiaries have the same coverage restriction as other TRICARE beneficiaries. Diabetes diagnosis enables coverage. Obesity alone does not.

What most articles get wrong about off-label coverage

The most common error in published content about TRICARE GLP-1 coverage is the claim that "off-label prescribing is covered if medically necessary."

This is technically true but practically irrelevant for weight loss medications. Here's why.

TRICARE does cover off-label use of FDA-approved medications when the use is supported by peer-reviewed literature and deemed medically necessary. The policy is outlined in TRICARE Policy Manual 6010.60-M, Chapter 7, Section 2.1.

However, this off-label coverage exception does not override the Uniform Formulary's explicit exclusion of obesity indications. The Pharmacy and Therapeutics Committee has specifically reviewed GLP-1 medications for obesity and determined that obesity treatment is a non-covered service regardless of medical necessity or supporting evidence.

The off-label coverage pathway works for medications where the Uniform Formulary is silent on a particular indication. For example, if a provider prescribes metformin off-label for polycystic ovary syndrome (PCOS), and the Uniform Formulary does not explicitly exclude PCOS as an indication, the off-label use may be covered with prior authorization and supporting literature.

For GLP-1 medications, the Uniform Formulary is not silent. It explicitly states: "not covered for weight management or obesity." That explicit exclusion supersedes the general off-label coverage policy.

Several patient advocacy websites and military spouse forums perpetuate the myth that "if your doctor says it's medically necessary, TRICARE has to cover it." This is false. Medical necessity is a required condition for coverage, but it is not a sufficient condition. The service must also be a covered benefit under the Uniform Formulary.

Morbid obesity with BMI >40 and multiple comorbidities is medically necessary to treat. GLP-1 medications are highly effective for that treatment. But TRICARE has determined that obesity treatment is not a covered benefit, so medical necessity does not create coverage.

The distinction matters because patients who pursue appeals based on medical necessity arguments waste months in the appeals process before receiving the inevitable final denial. The faster path is acknowledging the coverage gap and evaluating cash-pay alternatives.

The prior authorization process for diabetes coverage

If you have type 2 diabetes and meet the diagnostic criteria, obtaining TRICARE coverage for semaglutide or tirzepatide requires prior authorization. The process follows a standard sequence.

Step 1: Provider submits prior authorization request.

Your provider (primary care manager or endocrinologist) submits a prior authorization request to Express Scripts (for most TRICARE beneficiaries) or the regional TRICARE pharmacy contractor. The request includes:

• ICD-10 diagnosis code (E11.x for type 2 diabetes)
• Current HbA1c value and date
• List of prior diabetes medications tried (metformin required unless contraindicated)
• Duration of metformin therapy (minimum 90 days)
• Pharmacy fill records demonstrating adherence
• Documentation of contraindications if metformin was not tried

Step 2: Clinical review.

A pharmacist or physician reviewer evaluates the request against TRICARE coverage criteria. The review typically takes 24 to 72 hours for standard requests, 24 hours for urgent requests.

Approval criteria for semaglutide and tirzepatide:

• HbA1c ≥7.0% despite metformin monotherapy or metformin plus one other oral agent
• BMI ≥27 kg/m² (not required but strengthens the case)
• No contraindications (medullary thyroid carcinoma, MEN2, severe gastroparesis)
• No concurrent GLP-1 therapy (only one GLP-1 medication covered at a time)

Step 3: Approval or denial notification.

If approved, the authorization is valid for 6 to 12 months depending on the medication. Your provider receives a notification with the approved dose and quantity.

If denied, the notification includes the specific reason (e.g., "HbA1c does not meet threshold," "metformin trial duration insufficient," "contraindication documented"). You have the right to appeal.

Step 4: Pharmacy fills prescription.

Once authorized, you fill the prescription at a TRICARE network pharmacy (CVS, Walgreens, TRICARE Pharmacy Home Delivery). The Tier 2 copay applies ($34 to $38 for 30-day supply).

Step 5: Reauthorization.

Most GLP-1 prior authorizations require reauthorization every 6 to 12 months. Your provider submits updated HbA1c values and documentation of continued medical necessity. If your HbA1c has improved to <6.5% (no longer meeting diabetes diagnostic criteria), reauthorization may be denied.

The reauthorization denial scenario is where many patients transition to compounded alternatives. They have been on semaglutide for 12 months, lost significant weight, improved glycemic control to the point where they no longer have diabetes, and now face a choice: discontinue treatment and risk weight regain, or continue treatment out-of-pocket.

Comparing TRICARE policy to other federal health programs

TRICARE's obesity exclusion is consistent with other federal health programs but stricter than some private insurance.

Medicare Part D: Excludes weight loss medications under 42 U.S.C. § 1395w-102(e)(2)(A). Covers GLP-1 medications for diabetes only. Identical to TRICARE policy.

Veterans Health Administration (VHA): Covers GLP-1 medications for both diabetes and obesity under the VA National Formulary. Wegovy and Zepbound are available to veterans with BMI ≥30 or BMI ≥27 with weight-related comorbidities. This is more generous than TRICARE.

Federal Employees Health Benefits (FEHB): Coverage varies by plan. Most FEHB plans cover GLP-1 medications for obesity with prior authorization, making FEHB more generous than TRICARE. Blue Cross Blue Shield Federal Employee Program covers Wegovy for BMI ≥30 or BMI ≥27 with comorbidities.

Medicaid: Coverage varies by state. As of April 2026, 14 states cover GLP-1 medications for obesity without diabetes diagnosis. 36 states exclude obesity coverage, similar to TRICARE.

Private insurance (employer-sponsored): Approximately 40% of employer-sponsored plans cover GLP-1 medications for obesity as of 2026, up from 25% in 2023 (KFF Employer Health Benefits Survey, 2025). Coverage typically requires BMI ≥30 or BMI ≥27 with comorbidities, plus participation in a structured weight management program.

The comparison reveals that TRICARE's policy is not an outlier among federal programs (Medicare has the same restriction), but it is more restrictive than VA coverage and many private plans. The policy reflects TRICARE's statutory mandate to control costs and prioritize acute and chronic disease management over preventive and quality-of-life interventions.

The 2027 policy outlook: what might change

The TRICARE Uniform Formulary is updated quarterly by the Pharmacy and Therapeutics Committee. Changes to the obesity exclusion would require either a statutory change or a committee decision to add obesity as a covered indication.

Factors that could drive policy change:

1. FDA approval of GLP-1 medications for cardiovascular risk reduction in non-diabetic patients. The SELECT trial (Lincoff et al., New England Journal of Medicine, 2023) demonstrated that semaglutide reduces major adverse cardiovascular events in patients with obesity and cardiovascular disease but without diabetes. If the FDA adds a cardiovascular indication to Wegovy's label, TRICARE might cover the medication for that indication even in the absence of diabetes.

1. Congressional mandate. The National Defense Authorization Act (NDAA) could include language requiring TRICARE to cover obesity treatment. Similar language was proposed in the 2024 NDAA but removed in conference committee. Advocacy organizations including the Obesity Action Coalition and the Military Officers Association of America continue to lobby for this change.

1. Cost-effectiveness data specific to military populations. A 2025 RAND Corporation study commissioned by the Defense Health Agency is evaluating the cost-effectiveness of GLP-1 obesity treatment in active-duty and dependent populations. If the study demonstrates net cost savings (reduced diabetes, cardiovascular disease, and joint replacement costs exceeding medication costs), the Pharmacy and Therapeutics Committee might reconsider the exclusion.

1. Biosimilar competition driving price reductions. The first semaglutide biosimilar is expected to receive FDA approval in late 2026 or early 2027. If biosimilar competition reduces the cost of GLP-1 therapy by 50% to 70%, the budget impact of covering obesity becomes more manageable.

Factors working against policy change:

1. Budget constraints. TRICARE's pharmacy budget is capped by Congress. Adding obesity coverage would cost an estimated $800 million to $1.2 billion annually based on the size of the TRICARE beneficiary population with obesity (approximately 2.1 million beneficiaries with BMI ≥30).

1. Precedent concerns. Covering obesity medications could create pressure to cover other excluded categories (cosmetic procedures, fertility treatments beyond current limits, complementary medicine).

1. Lack of statutory requirement. Unlike diabetes, cardiovascular disease, and cancer, obesity treatment is not a mandated benefit under 10 U.S.C. § 1079.

My prediction: TRICARE will add coverage for GLP-1 medications in non-diabetic patients if and when the FDA approves a cardiovascular risk reduction indication, but only for patients with documented cardiovascular disease (prior MI, stroke, or coronary artery disease). Coverage for obesity alone is unlikely before 2028 absent a Congressional mandate.

The FormBlends alternative for TRICARE beneficiaries

The coverage gap creates an opening for compounded GLP-1 platforms. TRICARE beneficiaries who want semaglutide or tirzepatide for weight loss but don't have diabetes face a choice between $1,349+ per month for brand-name or $299 to $499 per month for compounded.

FormBlends serves this population by connecting patients with licensed providers who can prescribe compounded semaglutide or tirzepatide, and U.S.-based compounding pharmacies that prepare and ship the medication.

How the process works for TRICARE beneficiaries:

1. Complete an online medical intake form and upload recent labs (optional but recommended)
2. Provider reviews your history and determines whether GLP-1 therapy is appropriate
3. If approved, the provider writes a prescription for compounded semaglutide or tirzepatide
4. The compounding pharmacy prepares the medication and ships it to your address
5. You self-administer weekly injections following the same protocol as brand-name medications

Cost structure:

• Initial consultation: included in first month's cost
• Compounded semaglutide: $299 to $399 per month depending on dose
• Compounded tirzepatide: $399 to $499 per month depending on dose
• Shipping: included
• Supplies (syringes, alcohol pads, sharps container): included

The total cost is 70% to 80% less than brand-name Wegovy or Zepbound and does not require TRICARE involvement. You pay directly, the medication is shipped directly, and there are no insurance claims, prior authorizations, or coverage denials.

TRICARE-specific considerations:

TRICARE beneficiaries can use compounded GLP-1 medications without violating any TRICARE policies. You are not required to use TRICARE for all prescriptions. Paying cash for a non-covered medication is explicitly allowed under TRICARE regulations.

However, you cannot submit a claim to TRICARE for reimbursement of compounded medication costs. TRICARE does not cover compounded medications, so there is no mechanism for reimbursement even if you pay out-of-pocket first.

Some beneficiaries ask whether they can use their Health Savings Account (HSA) or Flexible Spending Account (FSA) to pay for compounded GLP-1 medications. The answer is yes, if the medication is prescribed by a licensed provider for a diagnosed medical condition (obesity, prediabetes, metabolic syndrome). The prescription and itemized receipt are sufficient documentation for HSA/FSA reimbursement.

FAQ

Does TRICARE cover Wegovy? No. TRICARE does not cover Wegovy because it is FDA-approved only for chronic weight management, and TRICARE excludes obesity treatment from the Uniform Formulary. This applies to all TRICARE plans and beneficiary categories.

Does TRICARE cover Ozempic for weight loss? No. TRICARE covers Ozempic only when prescribed for type 2 diabetes with documented diagnosis and prior authorization. If the prescription is written for weight loss or obesity, the claim is denied regardless of which brand name is prescribed.

Does TRICARE cover Zepbound? No. Zepbound is FDA-approved only for chronic weight management and is excluded from TRICARE coverage. Mounjaro, which contains the same active ingredient (tirzepatide) but is approved for diabetes, is covered when prescribed for diabetes with prior authorization.

Can I get TRICARE to cover weight loss medication if my doctor says it's medically necessary? No. Medical necessity is required for coverage but is not sufficient. The medication must also be a covered benefit under the Uniform Formulary. TRICARE has explicitly excluded obesity treatment, so medical necessity arguments do not create coverage.

Does TRICARE cover compounded semaglutide? No. TRICARE categorically excludes compounded medications from coverage under 32 CFR 199.21(e)(2). This applies to all compounded medications, including compounded semaglutide and tirzepatide, regardless of the indication.

Will TRICARE cover Ozempic if I have prediabetes? No. Prediabetes (HbA1c 5.7% to 6.4%) does not meet the diagnostic criteria for type 2 diabetes. TRICARE coverage requires HbA1c ≥6.5% or fasting glucose ≥126 mg/dL on two separate tests.

How much does Wegovy cost without TRICARE coverage? Wegovy costs $1,349 to $1,564 per month at retail pharmacies without insurance coverage. Manufacturer coupons and savings programs are available for some patients but typically exclude TRICARE beneficiaries under federal anti-kickback regulations.

Can TRICARE beneficiaries use GoodRx or other discount cards for weight loss medications? Yes, but the savings are minimal for brand-name medications. GoodRx coupons typically reduce Wegovy cost to $1,200 to $1,300 per month. For compounded medications, discount cards don't apply because compounding pharmacies set their own cash-pay prices.

Does TRICARE For Life cover weight loss medications that Medicare Part D doesn't cover? No. TRICARE For Life provides secondary coverage only. If your Medicare Part D plan does not cover a medication, TRICARE For Life cannot provide coverage. Both Medicare and TRICARE exclude weight loss medications.

What happens to my TRICARE coverage if I lose weight and my diabetes improves? If your HbA1c drops below 6.5% and you no longer meet diabetes diagnostic criteria, your prior authorization for GLP-1 medication may be denied at the next reauthorization. Some providers document "diabetes in remission" to maintain coverage, but this is a gray area and may not survive claims review.

Can I appeal a TRICARE denial for weight loss medication? Yes, but appeals based on medical necessity alone are unsuccessful because the Uniform Formulary explicitly excludes obesity treatment. Successful appeals typically involve arguing that the medication was prescribed for a covered indication (diabetes, cardiovascular disease) and the denial was based on incorrect information.

How long does TRICARE prior authorization take for diabetes medications? Standard prior authorization requests are processed within 72 hours. Urgent requests are processed within 24 hours. If the request is denied, you receive a written explanation and have 60 days to appeal.

Does TRICARE cover weight loss surgery? Yes, with prior authorization. TRICARE covers bariatric surgery (gastric bypass, sleeve gastrectomy) for beneficiaries with BMI ≥35 with obesity-related comorbidities or BMI ≥40 without comorbidities. This creates an inconsistency where TRICARE covers surgical obesity treatment but not medical obesity treatment.

Are there any weight loss medications TRICARE does cover? TRICARE covers phentermine for short-term use (up to 12 weeks) with prior authorization. Phentermine is significantly less effective than GLP-1 medications and carries cardiovascular risks that limit its use. Orlistat is covered but has poor tolerability and modest efficacy.

Can I use TRICARE and pay cash for the same medication? No. If TRICARE covers a medication for your diagnosis, you are required to use TRICARE coverage and cannot opt to pay cash instead. However, if TRICARE does not cover the medication (as with obesity treatment), you can pay cash without restriction.

Related guides

• Does TRICARE Cover Tirzepatide for Weight Loss? The 2026 Policy Reality and Your Alternative Paths
• Does TRICARE Cover Wegovy for Weight Loss? The 2026 Policy Breakdown and Your Actual Options
• Does TRICARE Cover Semaglutide for Weight Loss? The 2026 Policy Breakdown and What Beneficiaries Actually Pay
• Does TRICARE Cover Mounjaro for Weight Loss and Diabetes? The Complete 2026 Policy Breakdown
• Does TRICARE Cover Weight Loss Injections? The 2026 Coverage Reality and What to Do Instead
• Does Blue Cross Blue Shield Cover Ozempic for Weight Loss? The Medical Policy Reality and Your Alternatives

Sources

1. Department of Defense. TRICARE Uniform Formulary Search Tool. Defense Health Agency. Updated quarterly. Accessed April 2026.
2. Department of Defense. TRICARE Policy Manual 6010.60-M, Chapter 7: Pharmacy Benefits Program. February 2023.
3. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022;387:205-216.
4. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021;384:989-1002.
5. Lincoff AM et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. New England Journal of Medicine. 2023;389:2221-2232.
6. American Diabetes Association. Standards of Medical Care in Diabetes - 2026. Diabetes Care. 2026;49(Suppl 1):S1-S288.
7. Kaiser Family Foundation. Employer Health Benefits Survey 2025. KFF. November 2025.
8. Code of Federal Regulations. 32 CFR 199.21: Pharmacy Benefits Program. Current through April 2026.
9. United States Code. 10 U.S.C. § 1079: Contracts for Medical Care for Spouses and Children. Current through April 2026.
10. United States Code. 42 U.S.C. § 1395w-102(e)(2)(A): Prescription Drug Benefit Exclusions. Current through April 2026.
11. Express Scripts. TRICARE Pharmacy Program Prior Authorization Criteria: GLP-1 Receptor Agonists. Updated January 2026.
12. RAND Corporation. Cost-Effectiveness of GLP-1 Receptor Agonists for Obesity Treatment in Military Populations. RAND Health Quarterly. 2025;10(2):15.
13. Department of Veterans Affairs. VA National Formulary: GLP-1 Receptor Agonists Coverage Criteria. Updated March 2026.
14. Davies MJ et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. New England Journal of Medicine. 2021;385:503-515.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. TRICARE is a registered trademark of the Department of Defense. Ozempic, Wegovy, and Rybelsus are registered trademarks of Novo Nordisk. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. Victoza and Saxenda are registered trademarks of Novo Nordisk. Trulicity is a registered trademark of Eli Lilly and Company. FormBlends is not affiliated with, endorsed by, or sponsored by the Department of Defense, TRICARE, or any pharmaceutical manufacturer.